Status: Recruiting
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.
Participants needed: 434
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Vivace Therapeutics, IncUpdated: Apr 2, 2026Locations: 12
Eligibility criteria
Part 3 Combination Cohort A: Patients with pathologically diagnosed, metastatic... [+5]
Active brain metastases or primary CNS (central nervous system) tumors. [+8]